Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: Quality-of-life assessment

Xiaolei Zhou*, David Cella, David Cameron, Mayur M. Amonkar, Anthony Segreti, Steven Stein, Mel Walker, Charles E. Geyer

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: Quality-of-life assessment'. Together they form a unique fingerprint.

Nursing and Health Professions

INIS

Pharmacology, Toxicology and Pharmaceutical Science